Cencora, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cencora, Inc. on August 12, 2026. The report addresses a specific operational change regarding the Company's relationship with Walgreens and reaffirms fiscal year 2026 financial guidance.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the current period. The only quantitative financial metric disclosed is the reaffirmed adjusted diluted earnings per share (EPS) guidance range of $17.75 to $17.95 for fiscal year 2026.
Material Changes
- Walgreens Volume Shift: Beginning July 1, 2026, certain Walgreens volume previously serviced by Cencora outside of the prime vendor agreement began moving outside the Company.
- Prime Vendor Agreement: The prime vendor agreement with Walgreens remains unchanged and continues to constitute the vast majority of the Company's business with Walgreens.
- Segment Impact: This volume shift was fully contemplated in the Company's August 5, 2026 commentary regarding fourth-quarter expectations for its U.S. Healthcare Solutions segment.
Guidance, Outlook, and Risks
Cencora is reaffirming its previously issued adjusted diluted EPS guidance range of $17.75 to $17.95 for fiscal year 2026. The filing includes standard cautionary language regarding forward-looking statements, noting that actual results may vary materially due to uncertainties and changes in circumstances. Detailed risk factors are referenced in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2025.
Investor Verification Checklist
- Verify the specific dollar value or percentage of Walgreens volume moving outside the Company beginning July 1, 2026.
- Confirm the impact of this volume shift on the U.S. Healthcare Solutions segment's fourth-quarter revenue and operating margins.
- Review the August 5, 2026 commentary referenced in the filing for detailed context on the volume transition.
- Monitor subsequent filings for any updates to the fiscal year 2026 adjusted diluted EPS guidance range of $17.75 to $17.95.